Lab-on-a-chip for multiplexed newborn screening of lysosomal storage disorders

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$188,364.00
Award Year:
2007
Program:
SBIR
Phase:
Phase I
Contract:
1R43HD057713-01
Agency Tracking Number:
HD057713
Solicitation Year:
2007
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
ADVANCED LIQUID LOGIC
ADVANCED LIQUID LOGIC, 615 Davis Dr., Suite 800, RESEARCH TRIANGLE PARK, NC, 27709
Hubzone Owned:
Y
Socially and Economically Disadvantaged:
Y
Woman Owned:
Y
Duns:
140695474
Principal Investigator:
VAMSEE PAMULA
(919) 287-9010
vkp@liquid-logic.com
Business Contact:
RICHARD WEST
(919) 287-9010
rwest@liquid-logic.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Newborn screening is currently performed by collecting dried bloodspots from infants and then sending them to a lab for analysis. There is an increasing necessity to screen for a number of disease conditions for which therapies are becoming available. Lysosomal storage diseases alone number greater than 40. There is a need to minimize the blood collected for screening purposes while maximizing the number of conditions screened. Also, conventional laboratory analysis of blood samples in a birthing center is impractical. An automated, inexpensive, multi-analyte and multiplexed newborn screening analyzer will help reduce the blood analysis volume, reduce the time-to-result, and make the analyzer available at the point-of- delivery (birthing centers). Based on Advanced Liquid Logic's previous demonstrations of digital microfluidic manipulation of nanoliter-sized droplets of enzymatic reagents and sample for dispensing from on-chip reservoirs, high speed transport, mixing, splitting and dilution, and absorbance, fluorescence, and luminescence detection of the assays, a disposable lab-on-a-chip will be developed. Ultimately, a disposable lab-on-a-chip for newborn screening will be developed where one punch from the dried blood spot or fresh blood will be the input to the system and it outputs the screening results in a completely automated fashion. Phase I work will focus on fabricating a microfluidic platform upon which microliters of dried blood spot extracts, reference standards, and reagent droplets will be dispensed, transported, mixed, assayed, and disposed. Fluorescence assays for determining activities of enzymes involved in Pompe, Fabry, and Hurler diseases will be transitioned to droplet-based format. Demonstration of these enzymatic assays establishes the feasibility of a digital microfluidic chip for newborn screening.Advanced Liquid Logic, Inc. is developing a lab-on-a-chip that integrates clinical chemistry, immunoassays, DNA amplification, and DNA sequencing on its proprietary digital (droplet-based) microfluidic platform for clinical diagnostics. The proposed project aims at demonstrating the feasibility of performing newborn screening for lysosomal storage disorders including Pompe, Fabry, and Hurler diseases from a single dried blood spot obtained from the heelstick of a newborn using a microfluidic lab-on-a-chip.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government